Top 5 net profit of listed pharmaceutical enterprises in the first half of 2016

Recently, the semi annual report of 2016 of listed companies has been published successively, with the net profit of 5 pharmaceutical companies exceeding 1 billion yuan, with a year-on-year growth of more than 10% Among them, Kangmei pharmaceutical has the largest net profit of 1.766 billion yuan, and Hengrui pharmaceutical has the fastest growth rate of 23.85% year-on-year In the first half of 2016, Kangmei pharmaceutical realized a total operating revenue of 11203.4986 million yuan, an increase of 23.59% over the same period of last year, and a net profit of 176, 6.308 million yuan, an increase of 23.25% over the same period of last year, including 33.71%, 5.85%, 44.36%, 33.12% and 71.87% year-on-year growth in revenue from Chinese herbal pieces, trade in Chinese herbal medicines, trade in drugs, medical devices and health care products, respectively The company actively explores and practices the Internet of Chinese medicine industry chain, and creates the Internet plus mode featuring precise Chinese medicine products and services Deeply involved in the whole industry chain of traditional Chinese medicine, the system of "big health + big platform + big data + big service" was established A series of innovative business models such as "smart pharmacy" and "Kangmei e" have brought new growth points The first time equity incentive is introduced to help straighten out the mechanism and ensure the "Internet plus" big health strategy is fully landed The company has formed a whole industrial chain from traditional Chinese medicine planting to terminal, with obvious cost advantage In the aspect of traditional Chinese medicine planting, the planting area of ginseng in Xinkaihe has been further expanded, and the planting project of ginseng under the forest has been progressing smoothly In the first half of the year, the company has completed the construction of planting bases for white peony, peony bark and Platycodon grandiflorum The company is expanding the planting area, expanding the planting area and varieties to ensure the supply of medicinal materials Considering that the price of Chinese medicinal materials has stabilized and recovered, the business of Chinese medicinal materials is expected to accelerate growth In the first half of this year, SHP achieved an operating revenue of 59.695 billion yuan, up 17.16% year on year The net profit was 1.732 billion yuan, up 12.94% year on year In the pharmaceutical industry, the operating revenue was 6.411 billion yuan, up 5.34% year on year; in the pharmaceutical distribution, the operating revenue was 53.374 billion yuan, up 18.97% year on year; in the pharmaceutical retail, the operating revenue was 2.490 billion yuan, up 7.64% year on year   The company actively expands new business areas, through the joint venture established by its Shanghai Herbal Medicine Co., Ltd and Jincun, Japan, to give full play to and learn from the successful experience of Jincun Chinese medicine, promote the R & D, production and manufacturing business of products such as traditional Chinese medicine formula granules and traditional Chinese medicine extracts, especially in the field of high starting point traditional Chinese medicine formula granules, to quickly enter the market, form quality and variety Advantages In addition, the company established a hemodialysis center by promoting the cooperation mode with the hospital, and opened up the service, equipment, consumables, drugs and other industrial chains, generating value-added effect In the first half of this year, we completed the acquisition of Jiangxi Shangrao Pharmaceutical Co., Ltd and Beijing he'an Changtai pharmacy In the first half of the year, the merger and acquisition integration in the pharmaceutical business sector of the company was less, and the growth was mainly driven by endogenous factors Measures such as pharmacy trusteeship (99 have been trusteeship at present) and rich product lines have significant effect on the growth In the first half of 2016, Fosun Pharmaceutical realized an operating revenue of 6937.0912 million yuan, an increase of 17.15% over the same period of 2015 The net profit was 150.2664 million yuan, an increase of 15.10% over the same period of last year Among them: the group's pharmaceutical manufacturing and R & D business achieved an operating revenue of 4848716400 yuan, an increase of 17.67% over the same period; the medical service business achieved an operating revenue of 753117500 yuan, an increase of 11.67% over the same period The key to Fosun's rapid growth in today's low-speed industry lies in its long-term focus on innovation and R & D Statistics show that in the first half of this year alone, Fosun's R & D investment (including capitalization) totaled 488.6492 million yuan, an increase of 37.06% over the same period of 2015; there were 37 patent applications in the pharmaceutical manufacturing and R & D sector; 13 patents were granted, all of which were invention patents Fosun Pharmaceutical Group focuses on the core business of pharmaceutical manufacturing and R & D, adheres to product innovation, and further improves product competitiveness At the same time, the company continues to increase investment in the field of medical services, and has basically formed a strategic layout of high-end medical services in coastal developed cities, a combination of second and third tier city specialty and general hospitals In addition, the company actively promotes the internationalization strategy, accelerates the pace of international M & A (in the first half of the year, Fosun Pharmaceutical plans to invest US $1.2 billion to acquire gland Pharma), and improves the business scale In the first half of 2016, Yunnan Baiyao achieved an operating revenue of 10.452 billion yuan, an increase of 9.53% over the same period of last year, and a net profit of 1.388 billion yuan, an increase of 10.58% over the same period of last year Among them, the operating revenue of industrial products (self-made) is 4.544 billion yuan, with a gross margin of 61.23%; the operating revenue of wholesale and retail (drugs) is 5.891 billion yuan, with a gross margin of 6.01%; the operating revenue of other products is 217500 yuan, with a gross margin of 14.96%   Yunnan Baiyao group, guided by the strategy of "new Baiyao, great health", fully grasps the development direction of pharmaceutical health industry, based on the characteristics of Yunnan Baiyao, adheres to the principle of "medicine", strengthens brand operation, implements active sales strategy, focuses on products, market, market share and profit by building business model based on big data, mobile technology and Internet technology The profit ability is further improved and the operation quality is continuously enhanced In the first half of this year, the company made positive progress in new product cultivation, marketing innovation, etc The company has actively cultivated new products, including medicines, transdermal products, medical devices, health products, etc.; it has successively launched health products such as Taomi washing hair care products, essential oil, steam eye mask, etc In terms of marketing innovation, the company introduced Internet thinking, actively carried out wechat marketing, some products completed the wechat signing agency work, and the sales work went smoothly Hengrui Pharmaceutical Co., Ltd has advanced the strategy of scientific and technological innovation and international development, and its business performance has grown steadily In the first half of 2016, the operating revenue was 5.279 billion yuan, an increase of 20.36% year on year; the net profit attributable to shareholders of the listed company was 1.314 billion yuan, an increase of 23.85% year on year Table 2 shows that the operating revenue of tablet drugs is 1346.2029 million yuan, an increase of 40.69% over the previous year, and the gross profit margin is 89.28%, an increase of 2.59% over the previous year; the operating revenue of injection drugs is 3853.5498 million yuan, an increase of 15.24% over the previous year, and the gross profit margin is 86.89%, an increase of 1.31% over the previous year; the operating revenue of API is 73.8715 million yuan, a decrease of 9.93% over the previous year, and the gross profit margin is 29.76%, an increase of 19.30% over the previous year In terms of R & D, Hengrui pharmaceutical continued to increase R & D investment, with a total R & D cost of 489 million yuan in the reporting period, accounting for 9.26% of sales revenue In addition, the company obtained 37 clinical approvals in the first half of the year, including 3 innovative drugs, 64 domestic patent applications, 13 PCT patent applications, 11 domestic patent authorizations and 13 foreign patent authorizations In terms of internationalization, the company continues to strengthen the implementation of internationalization strategy and actively expand overseas market In the first half of 2016, the export business of APIs and preparations grew steadily, with overseas sales revenue reaching RMB 336 million, a year-on-year increase of 48.11% In the first half of the year, 21 products were developed and applied in many places, 4 new research products were developed, and 5 anda applications were submitted to the FDA of the United States; meanwhile, registration, application and development of Australian and New Zealand markets were discussed with cooperation companies, and development efforts of other emerging markets such as Russia, Mexico, Brazil and other countries were gradually strengthened Data source: 2016 semi annual report of listed companies